These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30596074)

  • 1. Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
    Uenami T; Ishijima M; Kanazu M; Kurebe H; Edahiro R; Nishida K; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Ann Transl Med; 2018 Nov; 6(22):444. PubMed ID: 30596074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
    Bylicki O; Guisier F; Monnet I; Doubre H; Gervais R; Janicot H; Perol M; Fournel P; Lamy R; Auliac JB; Chouaid C
    Medicine (Baltimore); 2020 Jan; 99(3):e18726. PubMed ID: 32011450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of immunotherapy for non-small cell lung cancer.
    Malhotra J; Jabbour SK; Aisner J
    Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression.
    Tozuka T; Seike M; Minegishi Y; Kitagawa S; Kato T; Takano N; Hisakane K; Takahashi S; Kobayashi K; Kashiwada T; Sugano T; Takeuchi S; Kunugi S; Noro R; Saito Y; Kubota K; Gemma A
    Onco Targets Ther; 2018; 11():5601-5605. PubMed ID: 30237726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.
    Zarogoulidis P; Chinelis P; Efthymiou C; Athanasiadou A; Mpikos V; Papatsibas G; Papadopoulos V; Maragouli E; Huang H; Trakada G; Kallianos A; Veletza L; Hohenforst-Schmidt W
    Respir Med Case Rep; 2017; 22():7-10. PubMed ID: 28761805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
    Usuda K; Niida Y; Iwai S; Funasaki A; Sekimura A; Motono N; Yamada S; Uramoto H
    Front Oncol; 2020; 10():689. PubMed ID: 32582526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
    Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
    Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports.
    Gohara K; Okazaki A; Takeda Y; Iwasa K; Shibata K
    Respir Med Case Rep; 2021; 33():101469. PubMed ID: 34401305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma.
    Hsu PC; Wang CW; Kuo SC; Lin SM; Lo YL; Huang AC; Chiu LC; Yang CT
    Biomedicines; 2020 Feb; 8(2):. PubMed ID: 32092879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
    Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
    Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Dhankhar P; Insinga RP; Chandwani S; Hsu DC; Lee MYK; Huang M; Pellissier J; Rai A; Achra M; Tan SC
    Pharmacoecon Open; 2020 Jun; 4(2):235-247. PubMed ID: 31531842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
    N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
    Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y
    Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.